Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways

Urologic Oncology
Hervé WallerandAlain Ravaud

Abstract

With 300,000 annually new cases worldwide, urothelial-cell carcinoma of the bladder (UCCB) is the second most common urologic neoplasm after prostate carcinoma. Non-muscle-invasive bladder cancer (NMIBC), which is not immediately life-threatening, represents 70% to 80% of these initial cases. Despite optimal treatment (transurethral resection with intravesical chemo- or immunotherapy), 70% of these NMIBC will recur, and 10% to 20% will progress, highlighting the need for a new therapeutic approach. Indeed, the identification of patients at high risk of disease recurrence and progression would be beneficial in predicting which patients with NMIBC would benefit from strict follow-up and which would benefit from a more aggressive therapy. To date, conventional treatment remains disappointing in terms of oncologic results and morbidity. The growing understanding in tumor biology has enabled the signaling pathways involved in bladder tumorigenesis and progression to be identified, but few molecular targets have been available until now. The encouraging results seen in various human carcinomas suggests that these new agents should become part of the arsenal of drugs available in the treatment of NMIBC, alone or in combination with al...Continue Reading

References

Jan 1, 1987·Annual Review of Biochemistry·M Barbacid
Jul 1, 1987·Experimental Cell Research·D W StaceyM R Smith
Dec 1, 1983·The Journal of Urology·N M HeneyI R Hawkins
Nov 10, 1994·The New England Journal of Medicine·D EsrigR J Cote
Feb 6, 1999·International Journal of Cancer. Journal International Du Cancer·K KitaA Watanabe
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ZujewskiK H Cowan
Aug 23, 2000·The Journal of Urology·F Millán-RodríguezJ Vicente-Rodríguez
Mar 27, 2001·International Journal of Cancer. Journal International Du Cancer·G P PrevostB Morgan
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L SantosC Lopes
Feb 26, 2004·Seminars in Oncology·Said M Sebti, Alex A Adjei
Aug 25, 2004·Cancer Cell·Colin P N DinneyBogdan Czerniak
Mar 8, 2005·Experimental Cell Research·Corine G M L'Hôte, Margaret A Knowles
May 3, 2005·Cytokine & Growth Factor Reviews·V P EswarakumarJ Schlessinger
May 18, 2005·Proceedings of the National Academy of Sciences of the United States of America·Eunice L KwakDaniel A Haber
Aug 20, 2005·Nature Reviews. Cancer·Xue-Ru Wu
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Dec 13, 2005·Carcinogenesis·Isabelle Bernard-PierrotFrançois Radvanyi
Jan 19, 2006·The Annals of Pharmacotherapy·Michael H Nelson, Christian R Dolder
Feb 24, 2006·Nature Reviews. Cancer·Stephen B Baylin, Joyce E Ohm
Mar 30, 2006·International Journal of Cancer. Journal International Du Cancer·Johanna M M van OersArndt Hartmann
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia HernándezFrancisco X Real
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anirban P MitraRichard J Cote
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tammie C YehEli Wallace
Mar 8, 2007·Journal of the National Cancer Institute·Rabiya S Tuma
Nov 22, 2007·World Journal of Urology·Yair LotanNúria Malats
May 7, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry L GomezGeorge W Sledge

❮ Previous
Next ❯

Citations

Oct 6, 2015·Nature Reviews. Urology·Ilaria LuccaShahrokh F Shariat
Apr 15, 2016·Expert Opinion on Drug Discovery·P A OliveiraR Pinto-Leite
Feb 7, 2017·Urologia·Ramanitharan ManikandanJoan Palou Redorta
Jun 25, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Ana BlancaAntonio Lopez-Beltran
Oct 18, 2019·Current Molecular Pharmacology·Samira BahramiAmirhossein Sahebkar
Dec 12, 2020·Nutrition and Cancer·Connor ChestnutShrikant Anant

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.